ABSTRACT
This chapter examines background elements which have led to the new science-industry rapprochement, discusses research and publication problems which have arisen. It analyzes conflicts between the models of sexuality favored by industry and sexology, and offers advice for preventing further erosion of sexology's liberatory mission despite the threats of commercialization. The chapter argues the creeping co-optation of sexology by the pharmaceutical industry represents a Faustian bargain, whereby in exchange for some new research and professional opportunities, sexology is in serious danger of selling out a unique and socially important sexual vision and role. The enormous political and economic changes in academia have further pushed sexologists into the arms of the pharmaceutical industry. Industry interests lie in maximizing profit and companies demand secrecy over information they see as essential to profitability. Maintaining scientific integrity itself is a problem when scientific information is produced under commercial auspices.
